NGS-based Reference Materials for Fusion and Somatic Variant Detection in Myeloid Cancers
Determining and using the most effective and safest treatment is of great importance in cancer disease management. Recently, a potential biomarker has been identified in immunotherapy: tumor mutational burden (TMB), an assessment of the number of relevant mutations in a tumor.
The large range of genetic aberrations and genes involved in Myelogenous malignancies and clonal diseases of hematopoietic progenitor cells which can lead to accumulation of immature blast cells in the bone marrow and peripheral blood, make Next Generation Sequencing (NGS) assays an important technology platform to determine these genetic changes. Download this free poster to learn about how we characterized our NGS-based Reference Materials for Fusion and Somatic Variant Detection in Myeloid Cancers.
Fill out the form to download our free poster.
Complete this form for your free download:
We’re committed to your privacy. SeraCare will not share or sell your data. View our privacy policy below for details.